DK3049073T3 - Sammensætninger og fremgangsmåder til destabilisering, ændring og dispergering af biofilm - Google Patents

Sammensætninger og fremgangsmåder til destabilisering, ændring og dispergering af biofilm Download PDF

Info

Publication number
DK3049073T3
DK3049073T3 DK14847319.2T DK14847319T DK3049073T3 DK 3049073 T3 DK3049073 T3 DK 3049073T3 DK 14847319 T DK14847319 T DK 14847319T DK 3049073 T3 DK3049073 T3 DK 3049073T3
Authority
DK
Denmark
Prior art keywords
disperger
destabilization
biofilm
procedures
compositions
Prior art date
Application number
DK14847319.2T
Other languages
English (en)
Inventor
Alexander Rickard
Nick Jakubovics
Derek S Samarian
Ethan Kolderman
Original Assignee
Univ Michigan Regents
Univ Newcastle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52744423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3049073(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Michigan Regents, Univ Newcastle filed Critical Univ Michigan Regents
Application granted granted Critical
Publication of DK3049073T3 publication Critical patent/DK3049073T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/14Streptococcus; Staphylococcus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Plant Pathology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nutrition Science (AREA)
DK14847319.2T 2013-09-24 2014-09-24 Sammensætninger og fremgangsmåder til destabilisering, ændring og dispergering af biofilm DK3049073T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881762P 2013-09-24 2013-09-24
US201461972920P 2014-03-31 2014-03-31
PCT/US2014/057235 WO2015048146A1 (en) 2013-09-24 2014-09-24 Compositions and method for destabilizing, altering, and dispersing biofilms

Publications (1)

Publication Number Publication Date
DK3049073T3 true DK3049073T3 (da) 2021-02-01

Family

ID=52744423

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14847319.2T DK3049073T3 (da) 2013-09-24 2014-09-24 Sammensætninger og fremgangsmåder til destabilisering, ændring og dispergering af biofilm

Country Status (11)

Country Link
US (2) US20160235698A1 (da)
EP (3) EP3049073B1 (da)
CN (3) CN110129352A (da)
AU (5) AU2014326756B2 (da)
BR (1) BR112016006584B1 (da)
DK (1) DK3049073T3 (da)
ES (1) ES2847388T3 (da)
MX (1) MX2016003791A (da)
PL (1) PL3049073T3 (da)
WO (1) WO2015048146A1 (da)
ZA (1) ZA201602797B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
BR112016006584B1 (pt) 2013-09-24 2022-11-29 University Of Newcastle Upon Tyne Uso de l-arginina e método para desestabilizar, alterar, e dispersar biofilmes
US9795579B1 (en) * 2017-04-24 2017-10-24 Knoze Jr. Corporation Oral microbiota promoting method
KR20200123146A (ko) * 2018-02-21 2020-10-28 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 이차 작용 방식을 갖는 새로운 항균제에 대한 조성물 및 방법
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US10927397B2 (en) 2018-10-16 2021-02-23 Sterilex, Llc Compositions, devices and methods for detecting biofilms
CN113226258A (zh) * 2018-12-26 2021-08-06 高露洁-棕榄公司 将口腔中的生物膜从病原性生物膜转变为健康生物膜的方法
AU2019417312B2 (en) * 2018-12-26 2022-12-15 Colgate-Palmolive Company Reduction of pathogenic bacteria using arginine
MX2021007646A (es) * 2018-12-26 2021-08-11 Colgate Palmolive Co Inhibicion de la coagregacion especifica por arginina.
CN110583697B (zh) * 2019-09-20 2021-04-06 浙江工商大学 去除铜绿假单胞菌生物膜用的高效化学生物制剂及其应用
US20220395442A1 (en) * 2019-11-08 2022-12-15 Colgate-Palmolive Company Methods of Modifying Biofilm
CN111299267B (zh) * 2020-02-12 2021-10-22 上海交通大学 一种基于群感效应的供水管网生物膜控制方法及其应用
WO2023114550A2 (en) * 2021-12-19 2023-06-22 The Trustees Of Columbia University In The City Of New York Engineering bacteria swarm patterns for spatiotemporal information encoding

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0065884B1 (en) 1981-05-27 1986-08-20 Unitika Ltd. Urethral catheter capable of preventing urinary tract infection and process for producing the same
EP1159951A1 (en) * 2000-06-02 2001-12-05 Societe Des Produits Nestle S.A. Use of exogenous lactic bacteria strain against Actinomyces naeslundii-related diseases
AU4816200A (en) * 1999-05-03 2000-11-17 Advanced Research And Technology Institute, Inc. Methods and compositions for controlling dental caries, and recombinant smaa polypeptides useful for same
AU2001286741A1 (en) * 2000-08-25 2002-03-04 Trustees Of Tufts College Methods and compositions for potentiating antibiotic action against persistent/tolerant pathogenic microorganisms
US20100021942A1 (en) * 2008-07-25 2010-01-28 Paul Freemont Cell-free expression system for the detection of bacterial biofilms
WO2010075419A1 (en) * 2008-12-22 2010-07-01 Micropure, Inc Composition and method for reducing demineralization of teeth
US9579269B2 (en) * 2010-06-23 2017-02-28 Colgate-Palmolive Company Therapeutic oral composition
JP5753271B2 (ja) 2010-10-27 2015-07-22 コルゲート・パーモリブ・カンパニーColgate−Palmolive Company アルギニンおよび炭酸カルシウムを含むオーラルケア製品ならびにその使用方法および製造方法
US9717929B2 (en) * 2010-12-07 2017-08-01 Colgate-Palmolive Company Dentifrice compositions containing calcium silicate and a basic amino acid
JP6038167B2 (ja) * 2011-10-31 2016-12-07 ケーン バイオテク インコーポレーテッド 口腔疾患を予防及び治療する組成物及び方法
CN103974688A (zh) * 2011-12-15 2014-08-06 高露洁-棕榄公司 口腔护理组合物
BR112016006584B1 (pt) 2013-09-24 2022-11-29 University Of Newcastle Upon Tyne Uso de l-arginina e método para desestabilizar, alterar, e dispersar biofilmes

Also Published As

Publication number Publication date
ES2847388T3 (es) 2021-08-03
EP3049073B1 (en) 2020-11-04
BR112016006584B1 (pt) 2022-11-29
MX2016003791A (es) 2017-01-20
AU2021202650A1 (en) 2021-05-27
AU2014326756A1 (en) 2016-04-07
EP3150715A1 (en) 2017-04-05
ZA201602797B (en) 2018-12-19
EP3831374A1 (en) 2021-06-09
EP3049073A1 (en) 2016-08-03
EP3150715B1 (en) 2018-11-14
AU2016202002A1 (en) 2016-04-21
AU2019271937A1 (en) 2019-12-19
EP3049073A4 (en) 2017-03-15
US20160235698A1 (en) 2016-08-18
BR112016006584A2 (pt) 2017-08-01
CN106029062A (zh) 2016-10-12
US10570401B2 (en) 2020-02-25
CN115177607A (zh) 2022-10-14
AU2016202002B2 (en) 2017-10-12
AU2019271937B2 (en) 2021-01-28
PL3049073T3 (pl) 2021-10-25
CN110129352A (zh) 2019-08-16
WO2015048146A1 (en) 2015-04-02
AU2022271381A1 (en) 2022-12-15
US20160304886A1 (en) 2016-10-20
AU2014326756B2 (en) 2019-08-29
AU2021202650B2 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
DK3049073T3 (da) Sammensætninger og fremgangsmåder til destabilisering, ændring og dispergering af biofilm
DK3556869T3 (da) Sammensætninger og fremgangsmåder til sekventering af polynukleotider
DK3022217T3 (da) Sammensætninger til modulering af tau-ekspression
DK2984166T3 (da) Sammensætninger til behandling af mpsi
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK2968208T3 (da) Behandling af kataplexi
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2906696T4 (da) Fremgangsmåder til modulering af c9orf72-ekspression
DK3087183T3 (da) Modulation af angiopoietin-3-lignende ekspression
DK3418447T3 (da) Fremgangsmåde til behandling af mikrofibrilleret cellulose
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK3027618T3 (da) Polymorf af syk-hæmmere
DK3071215T3 (da) Sammensætninger og fremgangsmåder til behandling af pulmonal hypertension
FI20155101A (fi) Nanofibrillaarinen selluloosakoostumus
DK3021838T3 (da) Behandling af fedme
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK3054782T3 (da) Fremgangsmåde til tørring af biomasse
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
DK2922955T3 (da) Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
DK2983695T3 (da) Fremgangsmåder, anvendelser og sammensætninger af tie2- agonister
DK3197868T3 (da) N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrol-negative allosteriske modulatorer af nr2b
DK2833884T3 (da) Anvendelse af ccr3-inhibitorer